MEDVASC – Semaglutide : multiples effets
Blog du Dr Jean-Pierre LAROCHE, médecin vasculaire sans filtre et pragmatique qui parle de Médecine Vasculaire et de l’actualité
Related Articles
MEDVASC – Semaglutide : multiples effets
Blog du Dr Jean-Pierre LAROCHE, médecin vasculaire sans filtre et pragmatique qui parle de Médecine Vasculaire et de l’actualité
Study Shows CV Mortality Hitting Harder in Rural America – American College of Cardiology
People who live in rural areas are dying from cardiovascular disease at a much greater rate than those living in urban areas, according to a…
Acetylation alchemy: how Nat10 shapes vascular health
This editorial refers to ‘NAT10 promotes vascular remodelling via mRNA ac4C acetylation’, by C. Yu et al., https://doi.org/10.1093/eurheartj/ehae707.
Cath Lab Conundrums CME Course from Mayo Clinic | Mayo Clinic Cardiovascular Education
Deep dive into the intricacies of interventional cardiology and examine current methods of managing complex cases in coronary, structural, and peripheral interventions with Mayo Clinic…
Active Learning for the Medical Sciences
Master the medical sciences faster through our active learning approach to anatomy, biochemistry, biology, neuroanatomy, neuroscience, and physiology. Ditki is the ideal resource for the…
Should Sex be a Factor in Deciding 3VD Patients’ Revascularization Strategy? – Editor’s Choice
Women with 3-vessel coronary artery disease have similar outcomes to men following placement of a drug-eluting stent using percutaneous coronary intervention but fare worse with…
When AI Chatbots Diagnose Better Than Physicians
This Medical News article is an interview with Stanford University’s Jonathan Chen, MD, PhD, and Ethan Goh, MBBS, MS, about their research on AI tools…
In Some Doctors’ Offices, the Weigh-In Is No Longer Required
It may be a longstanding practice, but critics say routine weight measurements are driving some patients away from care.
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
This editorial refers to ‘Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial’, by K.W. Mahaf
